Avicanna secures USPTO patent for oral cannabinoid delivery system

TORONTO — Avicanna has received a patent from the United States Patent and Trademark Office (USPTO) for its self-emulsifying drug delivery system (SEDDS) oral cannabinoid compositions and methods for treating neuropathic pain.

“Research, development, and evaluation of the potential role of cannabinoids in advanced drug delivery systems for therapeutic benefit have been at the core of the company’s mission since inception. We are excited about the possibilities of further clinical applications for cannabinoid treatments in neuropathic pain and working closely with healthcare providers to support patients in need,” said Aras Azadian, CEO.